# US 10,501,527 B2 · Mast cell stabilizers for treatment of hypercytokinemia and viral infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,501,527 B2
- Document ID: US10501527B2
- Status: Granted
- Kind: B2
- Application number: 15/697,835
- Filed: 2017-09-07
- Published: 2018-03-08
- Granted: 2019-12-10
- Earliest claimed: 2016-09-08
- Assignees: Emergo Therapeutics, Inc.
- Applicants: Emergo Therapeutics, Inc.
- Inventors: Robin Parish Hyde-DeRuyscher; Nancy Harlan Hyde-DeRuyscher; Elicia Kristine Hyde-DeRuyscher
- Web page: https://patentgrep.com/patent/US10501527B2

## CPC

- A61K 31/215: of carboxylic acids
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 38/1709: {from mammals}
- A61K 39/42: viral
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/52: Cytokines; Lymphokines; Interferons
- A61K 2039/505: {comprising antibodies}
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods for treating hypercytokinemia and viral infections associated with hypercytokinemia using a mast cell stabilizing compound, optionally in combination with an antiviral agent. The invention further relates to compositions and dosage forms comprising mast cell stabilizing agents, optionally with an antiviral agent.

## Claims

### Claim 1

A method of treating or ameliorating hypercytokinemia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of norketotifen or a pharmaceutically acceptable salt thereof, thereby treating or ameliorating the hypercytokinemia, wherein the hypercytokinemia is caused by an influenza virus infection or an influenza-like illness.

### Claim 2 (depends on 1)

The method of claim 1, further comprising administering to the subject an additional therapeutic agent for the influenza virus infection an or influeza-like illness.

### Claim 3 (depends on 2)

The method of claim 2, wherein the additional therapeutic agent is an anti-influenza agent.

### Claim 4 (depends on 3)

The method of claim 3, wherein the anti-influenza agent is oseltamivir.

### Claim 5

A method of treating or ameliorating an influenza virus or an influenza-like illness associated with hypercytokinemia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of norketotifen or a pharmaceutically acceptable salt thereof, thereby treating or ameliorating the influenza virus infection or influenza-like illness associated with hypercytokinemia.

### Claim 6 (depends on 5)

The method of claim 5, further comprising administering to the subject an additional therapeutic agent for the influenza virus infection or influenza-like illness.

### Claim 7 (depends on 6)

The method of claim 6, wherein the additional therapeutic agent is an anti-influenza agent.

### Claim 8 (depends on 7)

The method of claim 7, wherein the anti-influenza agent is oseltamivir.

### Claim 9 (depends on 1)

The method of claim 1, further comprising performing a physical treatment on the subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the physical treatment is surgery, transplantation, plasmapheresis, modulation of temperature, or any combination thereof.

### Claim 11 (depends on 2)

The method of claim 2, wherein the norketotifen or a pharmaceutically acceptable salt thereof and the additional therapeutic agent are administered in the same composition.

### Claim 12 (depends on 2)

The method of claim 2, wherein the norketotifen or a pharmaceutically acceptable salt thereof and the additional therapeutic agent are administered in separate compositions.

### Claim 13 (depends on 6)

The method of claim 6, wherein the norketotifen or a pharmaceutically acceptable salt thereof and the additional therapeutic agent are administered in the same composition.

### Claim 14 (depends on 6)

The method of claim 6, wherein the norketotifen or a pharamceutically acceptable salt thereof and the additional therapeutic agent are administered in separate compositions.
